导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.23% | 1914/4773 |
| 近一周 | -3.12% | 3703/5462 |
| 近一月 | -9.89% | 4912/5421 |
| 近一季 | -18.37% | 4690/5209 |
| 近半年 | -1.53% | 1621/4920 |
| 近一年 | 5.59% | 1579/4366 |
| 近两年 | 101.05% | 600/2954 |
| 近三年 | 59.18% | 455/2253 |
| 成立以来 | 112.35% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.99% 2050/4961 |
34.13% 965/5312 |
- - |
- - |
| 2025 | 47.03% 580/4813 |
-1.72% 2759/3635 |
2.88% 1297/4076 |
47.03% 492/4524 |
-1.10% 2824/4813 |
| 2024 | 12.55% 1235/3463 |
-3.55% 1521/2808 |
-6.13% 1859/3014 |
26.31% 272/3129 |
-1.58% 1754/3463 |
| 2023 | -17.15% 1715/2656 |
1.75% 1520/2280 |
-6.54% 1660/2385 |
-8.25% 1685/2515 |
-5.04% 1242/2655 |
| 2022 | -26.43% 1402/2207 |
-18.08% 1299/1919 |
5.52% 885/2016 |
-16.62% 1476/2113 |
2.07% 1048/2208 |
| 2021 | 13.42% 356/1822 |
-5.39% 920/1255 |
24.91% 102/1330 |
-5.95% 880/1466 |
2.05% 714/1822 |
| 2020 | 61.95% 119/1250 |
3.97% 97/1028 |
27.69% 125/1067 |
7.03% 807/1164 |
13.97% 317/1184 |
| 2019 | 39.72% 273/1092 |
31.78% 188/739 |
-9.40% 652/788 |
6.73% 115/850 |
9.64% 213/918 |
| 2018 | - - |
- - |
- - |
-11.18% 568/660 |
-10.26% 185/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信创业板ETF联接C VS. 长安沪深300非周期A(740101) |